The DSMB meets periodically to review the safety results to date (Merck is blind to these data) to be certain that patients on Vytorin are not experiencing any unexpected safety issues.
While the apocalyptic view that we face an imminent inflationary depression may be reading too much into the tea leaves, relying on bad data is like flying blind in a storm.